Middle dose level:1.0×10^6 U CAR+ T Cells/kg

2 trials

Sponsors

Zhongshan People's Hospital

Conditions

Advanced gliomasRelapsed/Refractory Acute Myeloid Leukemia

Early Phase 1

Clinical study on the safety and tolerability of targeting CD33 UCAR-T cell injection in patients with relapsed/refractory acute myeloid leukemia

RecruitingChiCTR2000039293

Zhongshan People's HospitalRelapsed/Refractory Acute Myeloid Leukemia

Start: 2021-01-01Updated: 2021-01-25

Phase 1

Objective to evaluate the safety and efficacy of B7-H3 ucar-t cell injection in the treatment of advanced glioma

RecruitingChiCTR2100042402

Zhongshan People's HospitalAdvanced gliomas

Start: 2021-01-21Updated: 2021-04-26